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Treatment of HIV now occurs largely within the primary care setting, and the 
principal focus of most visits has become the management of chronic disease states. The 
clinical pharmacist’s potential role in improving chronic disease outcomes for HIV 
patients is unknown. A retrospective cohort study was performed for HIV-positive 
patients also diagnosed with diabetes, hypertension, or hyperlipidemia.  Characteristics 
and outcomes in 96 patients treated by an interdisciplinary team which included a clinical 
pharmacist (i.e., the intervention group) were compared to those in 50 patients treated by 
an individual healthcare provider (i.e., the control group). Primary outcomes were 
changes from baseline over 18 month period of HbA1c, low density lipoprotein (LDL), 
and blood pressure, respectively. Secondary outcomes included number of drug-drug 
interactions, HIV viral load, CD4 count, percent change in smoking status, and percent of 
patients treated to cardiovascular guideline recommendations. The interdisciplinary team 
had a significant improvement in lipid management over the control group (LDL: -8.8 vs. 
+8.4 mg/dL; p=0.014), and the smoking cessation rate over the study period was doubled 
in the interdisciplinary group (20.4% vs. 11.8%). Among those with an indication for 
aspirin, a significantly higher percentage of patients were prescribed the medication in 
the interdisciplinary group compared to the control group (85.5% v. 64.9%; p=0.014). An 
informal cost analysis estimated savings of more than $3000 per patient treated by the 
interdisciplinary team.  Based on these results, pharmacist involvement in an HIV 
primary care clinic appears to lead to more appropriate management of chronic co-
morbidities in a cost-effective manner. 
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INTRODUCTION 
At the beginning of the human immunodeficiency virus (HIV) epidemic, 
diagnosis with an HIV positive status warranted a medical response focused on treating 
opportunistic infections and providing palliative care. Today, medical management of 
HIV includes co-morbidities, drug interactions, and other non-AIDS related 
complications typical of the aging process. Due to the increase in options and quality of 
treatments, patients with HIV can now have the same life expectancy as a person from 
the general population provided that adherence to antiretroviral medications is 
maintained.1-3 It was estimated over 1.2 million people live with HIV infection in the 
United States today.4 The percentage of persons living with HIV who are 55 years of age 
or more increased from 13.2% in 2006 to 17.1% in 2009.5 By the year of 2015, it has 
previously been extrapolated that half of those living with HIV infection will be 50 years 
of age or older.6-7  
It has even been noted that people with HIV may live longer than those without it 
because of closer follow-up as they age.8 With this increase in longevity, the paradigm of 
managing patients with HIV has shifted. Opportunistic infections are far less prevalent 
than they once were. Effective antiretroviral therapy, even for resistant patients, is readily 
available. Many patients are now cared for by HIV primary care clinics, with the 
challenge of most visits primarily being treatment of other chronic disease states such as 
diabetes, hypertension, and hyperlipidemia.  
Appropriate management of such non-infectious co-morbidities is a challenge in 
any population, but may correlate to a higher burden of disease for individuals infected 
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with HIV. Growing evidence suggests that HIV may accelerate inflammatory processes 
which promote atherosclerosis, and an increased risk of cardiovascular disease (CVD) in 
this population has been well established.9-10 Certain antiretroviral drugs are also known 
to induce metabolic changes such as dyslipidemia, lipodystrophy, and insulin 
resistance.11-13 The most common medical co-morbidities for HIV-infected veterans 60 
years of age or older were previously defined as hypertension (45%), diabetes (21%), and 
vascular disease (23%).14 Additionally, HIV-infected individuals may have a higher 
prevalence of co-morbidities than uninfected individuals of the same age.15 The AGEhIV 
study specifically showed higher rates of hypertension, myocardial infarction, peripheral 
arterial disease, and renal disease in those with HIV as compared to the general 
population.16 In the New York metropolitan area, where this study was performed, there 
are an estimated 140,000 people living with HIV.17 Prevalence rates of hypertension, 
hyperlipidemia, and diabetes have been identified as 26%, 48%, and 13% in a Bronx 
institution serving an urban, low-income, HIV-positive population similar to ours.18 
 The pharmacist’s role in management of both HIV and chronic disease states has 
continued to expand over the years. In 2011, the American Academy of HIV Medicine 
developed a new program to certify pharmacists specializing in HIV management 
(AAHIVP).19 Additionally, the Department of Human & Health Services (DHHS) 
HIV/AIDS Guidelines recommend the use of multidisciplinary teams, including 
pharmacists, as the optimal practice model.20 The advent of collaborative drug therapy 
management (CDTM) allowed pharmacists to further expand their role in patient care 
with New York State (NYS) becoming the 47th state to sign a CDTM bill into law on 
September 12, 2011. Pharmacists where CDTM has been made legal may perform patient 
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assessments, order drug-related laboratory tests, administer drugs, and select, initiate, 
monitor, continue, or adjust drug regimens under a pharmacist-physician agreement.21  
 The use of CDTM to improve patient outcomes in chronic disease states has been 
extensively addressed and demonstrated in the literature.22-24 A meta-analysis on the role 
of team-based care involving pharmacists to improve cardiovascular and renal outcomes 
found patients in the team-based care group to have reduced blood pressure, LDL, 
HbA1c, and in heart failure patients, reduced all-cause mortality, heart failure events, and 
hospitalization rates as compared to the usual care group.22 The impact of CDTM on HIV 
treatment outcomes has also been studied, primarily in settings such as pharmacist-driven 
adherence clinics or outpatient pharmacies.25 Relevant interventions have been classified 
as medication adherence counseling, patient education, increased rates of HIV testing, 
antiretroviral regimen selection/initiation/discontinuation, dose adjustment for 
renal/hepatic impairment, and monitoring for adverse effects and drug interactions.25-29  
 In an HIV-primary care clinic which utilizes an interdisciplinary model, such as 
the Program for AIDS Treatment & Health (PATH) Center of The Brooklyn Hospital 
Center located in Brooklyn, NY, the clinical pharmacist does the aforementioned and 
more. Along with the primary medical provider, the pharmacist is simultaneously 
involved with managing antiretroviral medications in addition to the patient’s chronic 
disease states. A patient satisfaction study was conducted at our clinic and indicated that 
overall satisfaction scores for this interdisciplinary practice model were high and a 
positive perception was found among patients.  Patients indicated a preference for this 
particular clinic owing to the interaction between physicians, pharmacists, nurses and 
social workers.30 Despite this patient endorsement, there has been no published literature 
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to date evaluating the impact of including a clinical pharmacist in the interdisciplinary 
team practice model of an HIV-primary care clinic on both chronic diseases and HIV 
outcomes. The objective of this study was to determine if the addition of a clinical 
pharmacist to the treatment of HIV patients improves outcomes for chronic disease states, 
in addition to HIV. If such a collaborative approach is shown to improve selected clinical 
values over a usual care group, the results could be applicable to HIV primary care clinics 
nationwide. 
METHODS 
This study was a retrospective cohort study of HIV-positive patients seen at the 
PATH Center from June 2012 through December 2013. The “interdisciplinary group” 
served as the intervention group, including a clinical pharmacist in addition to a medical 
provider. As our institution is a teaching hospital, this group may also include medical 
and pharmacy residents and students. Both medical and pharmacy disciplines collaborate 
to determine a final plan of care. Patients who prefer a more private treatment setting may 
opt out of the interdisciplinary group and be seen individually by a separate physician, 
nurse practitioner, or physician assistant. These providers do not participate in the 
interdisciplinary team model and patients under “solo provider” care served as the control 
group. This research study received Institutional Review Board (IRB) approval.  
As the interdisciplinary group contains members from medical and pharmacy, it 
can be difficult to assign study outcomes to one specific member of the team. To 
eliminate measurement bias, potential study subjects from the interdisciplinary group 
were determined based on the presence of documented interventions by the pharmacy 
team during 2011-2012.  All interventions made by a pharmacist are documented in the 
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paper medical chart and electronic medical record. Only patients from the 
interdisciplinary group with documented pharmacist interventions were reviewed for 
inclusion to ensure the clinical pharmacist had played an integral role in the patient’s care. 
Two hundred and twenty such patients were identified and further reviewed for inclusion.  
Other inclusion criteria consisted of age greater than or equal to 18 years, 
diagnosis of HIV or AIDS (defined as CD4 <200 cells/mm3 at any point in patient’s 
history), consistent follow-up with the PATH center from June 2012 through December 
2013 (defined as at least 1 visit every 6 months), and past medical history including 
diabetes, hypertension, or hyperlipidemia. Patients were excluded from the study if they 
were lost to follow-up or did not have at least one of the co-morbidities. Ninety-six 
patients in the interdisciplinary group were found to meet inclusion criteria. The minimal 
required sample size (96:48= interdisciplinary:solo) was calculated based on 80% power 
at a two-tailed alpha of 0.05 using independent t-tests to detect a difference in two means 
of the primary outcomes (i.e., 10 mmHg in systolic blood pressure, 20 mg/dL in low 
density lipoprotein [LDL] cholesterol, and 1% in HbA1c). The comparator group of 50 
solo-provider patients was selected using block randomization from a data query which 
identified patients seen over the 18-month study period and prescribed anti-hypertensives, 
lipid lowering agents, or anti-diabetics.  
As it is plausible that either group could have seen more complicated patients, the 
Charlson Co-morbidity Index (CCI) Scoring System was applied to indicate each 
patient’s severity level for use as a potential confounding variable. This system represents 
a 10-year mortality risk score and has been validated in both in-patient and out-patient 
settings.24,31 The CCI score was calculated based on patient diagnoses at the beginning of 
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the study period. Although the CCI scoring system assigns a score of 6 points to patients 
with a diagnosis of AIDS, for our purposes only patients with actively uncontrolled 
disease and CD4 <200 mg/dL were assigned 6 points towards their total score, 
considering most of our patients with an AIDS diagnosis have recovered immune 
function.32 
Electronic medical records of eligible study subjects were retrospectively 
reviewed and the 18-month follow-up data were collected. The primary outcome was the 
change from patient’s own baseline for systolic and diastolic blood pressure, LDL 
cholesterol, and HbA1c, which were chosen as surrogate markers for hypertension, 
hyperlipidemia, and diabetes due to the implications of disease control on risk of 
cardiovascular events. Secondary outcomes included differences between treatment 
groups in HIV-related outcomes such as number of drug-drug interactions, viral load, and 
CD4 counts. Other secondary outcomes were also chosen for their potential impact on 
cardiovascular disease (CVD) including appropriate use of low-dose aspirin, percent 
change in reported smoking status, and percent of patients treated according to guideline 
recommendations. This included appropriateness of cardiovascular medications per JNC 
7 and ACC/AHA Joint Guidelines and medication therapy for stroke, coronary artery 
disease, and congestive heart failure as per most recent AHA guidelines.33-37  
Smoking cessation is of particular concern for HIV-infected individuals as it is 
more prevalent in this population and has been shown to contribute to elevated CVD risk, 
increased rates of pulmonary diseases, and increased infections.38-40 During clinic visits, 
smoking cessation was addressed by all providers, however pharmacists were responsible 
for assessing readiness to quit and initiating smoking cessation agents such as nicotine 
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replacement therapy, bupropion, or varenicline. Fagerstrom scores and motivational 
counseling were utilized and additional counseling or follow up was provided by 
pharmacists on subsequent visits.  
All statistical analyses were performed using IBM Statistical Package for Social 
Sciences (SPSS version 21, SPSS Inc., Chicago, Illinois) at the significance level of 0.05 
(two-tails). Viral load was stratified into <200, 200-500, or >500 and CD4 into ≤500 
cells/mm3 and >500 cells/mm3 before statistical analysis was performed. Independent t-
test was used to compare normally distributed data and Mann-Whitney U test (a non-
parametric test) was used to compare non-normally distributed data in baseline 
characteristics and outcome measures between two groups. Fisher-exact test and chi-
square test were used to compare percentages between two study groups. When p<0.10 
was found in comparison of subject characteristics between two groups, this 
characteristic was treated as a potential confounding factor and included as an 
independent variable in the regression models. Linear regression analyses with the 
forward stepwise method were performed to identify potential covariates.  General linear 
model was used to adjust final measures of primary outcomes for the covariate(s).  
RESULTS 
Baseline characteristics and distribution of co-morbidities is reported in Table 1. 
Although the interdisciplinary group had significantly lower rates of co-morbid 
hypertension (p=0.043), higher baseline values for systolic BP (p=0.042), diastolic blood 
pressure (p=0.005), and LDL (p=0.003) were found. The interdisciplinary group had 
more medications (10.6 vs. 8.8; p=0.005), but fewer drug-drug interactions than the solo 
provider group (0.14 vs. 0.38; p=0.008) when considering combinations which are 
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contraindicated or recommended to consider avoiding. More patients were reported as 
smokers in the interdisciplinary group, however this number did not achieve statistical 
significance (p=0.050). Other baseline measures and characteristics were comparable 
between groups, including CCI score and HIV-related measures.  
Primary outcomes are reported as either final measures or the difference from 
baseline to final value (Table 2). There was no significant difference between groups for 
change in systolic BP (p=0.619), diastolic BP (p=0.366) or HbA1c (p=0.190). A 
significant change in LDL was found with the interdisciplinary group over the solo 
provider group (-8.8 vs. +8.4 mg/dL; p=0.014).  
The two groups had similar results in terms of achieving “goal” BP, LDL, and 
HbA1c at final visit. Results of secondary outcomes are shown in Table 3. More patients 
in the interdisciplinary group as compared to the solo provider group had appropriate 
therapy prescribed for compelling cardiovascular indications (71.6% vs. 60%), but the 
difference was not statistically significant. Among those with an indication for aspirin, a 
significantly higher percent of patients (85.5%) were prescribed the medication in the 
interdisciplinary group, compared to only 64.9% in the solo provider group (p=0.014). 
Among smokers at baseline, the smoking cessation rate over the study time period was 
doubled in the interdisciplinary group (20.4%) compared to that in the control (11.8%); 
however, no significant statistical difference was found (p=0.714). There continued to be 
significantly fewer drug-drug interactions identified in the interdisciplinary group at the 
end of follow-up (p=0.023); however, the significance disappears when baseline measure 
was considered (p=0.432). Regarding HIV-related outcomes, no statistically significant 
difference was identified for either baseline or final value for CD4 and viral load.  




This is the first piece of literature describing an interdisciplinary team model with 
such close collaboration between medical and pharmacy providers in an HIV primary 
care setting. Although many studies have reported the benefit of clinical pharmacist 
involvement for improvement of HIV outcomes25-29, none have yet evaluated the benefit 
of such collaborative practice on outcomes for chronic co-morbidities. In this study, 
patients seen by the interdisciplinary group tended to be more complicated, with 
statistically higher baseline values for blood pressure and LDL cholesterol, although CCI 
was not significantly different between groups. 
While the most recently updated cholesterol guidelines published in late 2013 
have represented a controversial shift away from numerical LDL goals in favor of 
appropriate prescribing41, it is still important to note the significant reduction in 
cholesterol lowering seen with the interdisciplinary group as patients with HIV are at a 
higher risk for developing coronary artery disease.9-10 The reduction in LDL cholesterol 
were reflective of pharmacist recommendations of using more appropriate intensity 
statins. Additionally, although there was no statistical difference between groups 
regarding blood pressure control, these results are likely no longer relevant as blood 
pressure goals for primary prevention have become more lenient with the updated 
hypertension guidelines published in late 2013.42 
Although no statistically significant difference was seen between groups in 
regards to better blood pressure or diabetes control, the HbA1c reduction of 1.3% seen in 
the interdisciplinary group may still be interpreted as clinically significant.  In addition to 
the clinical pharmacist involvement in routine clinic visits, patients may also be referred 
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for individual appointments with the pharmacist if further counseling or education is 
requested. Uncontrolled diabetes represents a significant portion of these one-on-one 
referrals and such positive diabetes outcomes may be a reflection of this individual 
attention.  As only 17 patients from the solo provider group and 29 patients from the 
interdisciplinary group were included in this part of the analysis, it is likely that the study 
was underpowered to detect a significant difference between groups.  
The PATH Center serves a primarily Medicaid population with approximately 
99% of patients living below the federal poverty level. The care of such patients is often 
complicated by psychiatric and socioeconomic issues such as drug abuse, depression, and 
unemployment.43 Due to such confounding factors, it was suspected that many patients 
may not achieve therapy goals due to issues with medication access and adherence, rather 
than inappropriate prescribing habits. This seemed to be true for the interdisciplinary 
group as only 53.3% of patients achieved adequate blood pressure control over the study 
time period despite 71.6% being prescribed appropriate therapy. Our interdisciplinary 
group overall was shown to be more thorough in their prescribing habits, specifically for 
compelling cardiovascular medications and aspirin for primary or secondary prevention 
as per JNC, NCEP, AHA, ASA, ACCF, and the U.S. Preventative Services Task Force 
(USPSTF) recommendations.33-37,44  
 Smoking cessation can also be more difficult to address in an urban population, 
particularly in HIV patients who have a high rate of tobacco use. Traditional therapies, 
such as nicotine replacement therapy, varenicline, and bupropion have been shown to 
facilitate abstinence in HIV-positive smokers.45 Unique interventions to address smoking 
cessation in this population have included nurse-driven interventions, culturally tailored 
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group-based sessions for African-American MSM, and cell-phone delivered intensive 
counseling sessions, all combined with nicotine replacement therapy (NRT).46-48 Studies 
have suggested that helping HIV-positive smokers develop adaptive strategies to cope 
with HIV symptom distress may be an effective approach to cessation.49 It is 
hypothesized that the heightened awareness and willingness to prescribe pharmacologic 
interventions by the pharmacy team is behind the doubled rate of smoking cessation in 
the interdisciplinary group.  
Even though there are significant differences in total number of medications 
(p=0.0014) and drug-drug interactions (p=0.008) between two groups at baseline, both 
groups had a similar pattern of reduction in drug-drug interactions during the entire study 
time period (p= NS after adjusting final values for baseline). Certain interactions, such as 
acid-suppressant medications and rilpivirine or atazanavir, can compromise the efficacy 
of a patient’s antiretroviral regimen.  In addition, ritonavir or cobicistat based regimens 
often result in drug interactions concerning patient safety.  Therefore, recognition of 
interactions is a tremendously important part of any HIV patient’s care.50 
 We did not expect to find any difference between groups for CD4 counts and viral 
loads as successful management of these outcomes has become routine since the 
development of highly active antiretroviral therapy. All providers at the clinic are 
experienced and fully competent in choosing safe and effective regimens for their 
patients, with consideration always given to resistance and adherence. As long as patients 
are compliant with their medications, the CD4 and viral load are expected to respond 
appropriately. The study data supported our argument by showing no statistical difference 
between groups at either baseline or final visit for CD4 or viral load. While several 
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studies have reported a significant reduction in viral load with pharmacist involvement51-
55, most of these studies were not performed in an HIV primary care clinic such as ours 
where addressing antiretroviral adherence and simplifying regimens is an integral part of 
each visit. The true impact of this study was shown in the patient’s chronic co-
morbidities which, as described in the introduction, are frequently now the focus of HIV 
primary care visits. 
Possible limitations for the study include its retrospective design and small 
sample size for each disease state evaluated. Although the pre-specified number for 
inclusion was met, power may not have been achieved for disease state specific outcomes 
as not every patient reviewed had all three co-morbidities. While measures were taken to 
establish if one group of patients was more medically complicated than the other, 
differences in psychiatric capacity or socioeconomic status were not captured. These and 
other confounding variables could have represented significant barriers to medication 
access or adherence, which subsequently could have influenced outcomes. It is also 
important to note patient self-selection as a study bias. The intervention and control 
groups are not randomized as the patient chooses who they would like to receive care 
from. Personality traits and factors which influence this private decision are unaccounted 
for in our analysis. The interdisciplinary group also involves medical residents which 
may be cited as another difference between the intervention and control groups. However, 
all patients included in the interdisciplinary group were identified only from a pool of 
patients with documented pharmacist interventions, suggesting that the presence of a 
clinical pharmacist had significantly impacted the patient’s care. Lastly, this study was 
based on the goals and therapy recommendations of previous disease state guidelines. 
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Although aforementioned updated guidelines were recently released41-42, the guidelines 
used in the methodology of this study were considered the gold standard for the vast 
majority of the follow-up time period. 
Despite being a small, single-center study, it is the first of its kind to address the 
benefit of HIV clinical pharmacist involvement in an HIV primary care clinic for disease 
state outcomes beyond just HIV. The results of this study showed pharmacist 
involvement to be beneficial for lipid management, as well as improvement in diabetes, 
smoking cessation rates, adherence to optimal prescribing recommendations, appropriate 
use of aspirin, and reduced drug-drug interactions. It is important to note that although 
this study primarily reported surrogate markers of cardiovascular disease, interventions 
by the pharmacist at this clinic were previously quantified in many additional disease 
states, such as asthma/COPD, chronic pain, Hepatitis C co-infection, and 
anticoagulation.56 
Although the benefits of incorporating a clinical pharmacist into the HIV primary 
care setting are numerous, cost may be viewed as a significantly limiting factor. This 
study was not originally designed to compare costs between the two study groups. 
However, we may informally estimate potential cost savings based on values from the 
literature and databases of commercially available insurance claims in regards to our 
study outcomes (Table 4).57-61 All values are converted to 2015 US dollars based on the 
Consumer Price Index62. As these cost estimates are synthesized from different sources, 
patient cohorts, settings, and study years, interpretations should be made cautiously. It 
was estimated that $3329 per patient would be saved for the interdisciplinary group in 
terms of financial returns on smoking cessation and emergency department/hospital 
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utilization due to hypertension, diabetes mellitus, hyperlipidemia, and drug-drug 
interactions. This value may be over-estimated when compared to our results, as not all of 
these outcomes achieved statistical significance. To our knowledge, there is no 
pharmacoeconomic study evaluating the effects of a multidisciplinary team with 
pharmacist interventions for HIV-infected patients. Future research in this area is 
warranted to further justify our results.  
CONCLUSION 
Pharmacist involvement in an HIV primary care clinic appears to result in more 
appropriate management of chronic co-morbidities in a cost-effective manner, although 
positive long-term outcomes may be difficult to establish in a complicated, urban 
population. We believe this data supports the expansion of clinical pharmacist 
involvement in HIV primary care centers to establish interdisciplinary team models as the 
standard for best practice. 
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Females [n(%)] 23 (46%) 46 (48%) 0.826 
Age, years [mean (SD)] 54.5 (7.5) 54.0 (7.6) 0.500 
Hypertension [n(%)] 39 (78%) 59 (62%) 0.043 
Hyperlipidemia [n(%)] 39 (78%) 70 (73%) 0.503 
Diabetes [n(%)] 17 (34%) 27 (28%) 0.463 
Systolic blood pressure, mmHg 
[median (ICQ)] 
132 (125, 142) 140 (130.5, 
150.5) 
0.042+ 
Diastolic blood pressure, mmHg 
[median (ICQ)] 
82 (77, 89) 89 (81, 96) 0.005+ 
LDL colesterol, mg/dL [mean (SD)] 97 (34) 120 (38) 0.003 





No. of CHD risk factors [mean 
(SD)] 
1.25 (0.99) 1.73 (1.07) 0.079 
No. of medications [mean (SD)] 8.8 (3.19) 10.6 (4.59) 0.014 
No. of drug-drug interactions    
0 33 (66%) 83 (87.4%) 0.009 
1 15 (30%) 11 (11.6%)  
2 2 (4%) 1 (1.1%)  
mean (SD) 0.38 (0.57) 0.14 (0.38) 0.008 
Smoking [n(%)] 17 (34%) 49 (51%) 0.050 
Charlson Comorbidity Index [mean 
(SD)] 
1.78 (1.88) 2.23 (1.98) 0.185 
CD4 ≥500 mmHg [n(%)] 29 (58%) 48 (50%) 0.358 
Viral load [n(%)]    
0.380 <200 copies/mL 40 (80%) 78 (81%) 
200-500 copies/mL 1 (2%) 0 (0%) 
>500 copies/mL 9 (18%) 18 (19%) 
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+Mann-Whitney U test was performed for non-normally distributed data 
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TABLE 2: PRIMARY OUTCOME RESULTS 





Systolic blood pressure, mmHg     
Final measure [median (ICQ)] 130.5 (122, 141.5) 134 (120, 149.5) 0.3471 
Final measure [mean (SD)] 132.3 (17.8) 137.6 (23.8) 0.9642 
Change from baseline [median (ICQ)] +2 (-12, +7.75) -4 (-14, +8.5) 0.6191 
Diastolic blood pressure, mmHg    
Final measure [median (ICQ)] 80 (72, 89.5) 82 (75.5, 91) 0.2221 
Final measure [mean (SD)] 80.6 (10.2) 84.5 (12.8) 0.6913 
Change from baseline [median (ICQ)] -3.5 (-8, 4.75) -7 (-12, +7) 0.3661 
LDL cholesterol, mg/dL     
Final measure [mean (SD)] 103 (34.7) 111 (35.3) 0.3564 
Change from baseline [mean (SD)] +8.4 (30.3) -8.8 (35.6) 0.0145 
HbA1c (%) n=17 n=29  
Final measure [mean (SD)] 7.33% (1.78%) 6.97% (1.62%) 0.2036 
Change from baseline [mean (SD)] -0.44% (1.43%) -1.30% (2.34%) 0.1905 
1Mann-Whitney U test was performed for non-normally distributed data 
2General linear model was performed to adjust for covariates: baseline systolic blood 
pressure (p<0.001) and Charlson Comorbidity Index (p=0.007) 
3General linear model was performed to adjust for covariates: baseline systolic blood 
pressure (p<0.001) and Charlson Comorbidity Index (p=0.075) 
4General linear model was performed to adjust for covariate: baseline LDL (p<0.001) 
5Independent t-test was performed 
6General linear model was performed to adjust for covariate: baseline HbA1c (p<0.001) 
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Final systolic blood pressure at goal 24/39 (61.5%) 32/60 (53.3%) 0.421 
Final LDL at goal 24/36 (66.7%) 52/73 (71.2%) 0.626 
Final HbA1c at goal 11/17 (64.7%) 21/29 (72.4%) 0.583 
Appropriate cardiovascular therapy 
prescribed 
21/35 (60%) 43/60 (71.6%) 0.242 
Aspirin indicated 37/50 (74%) 69/96 (71.9%) 0.785 
Aspirin prescribed 27/49 (55.1%) 64/96 (66.7%) 0.173 
Aspirin prescribed among those with an 
indication for aspirin 
24/37 (64.9%) 59/69 (85.5%) 0.014 
Smoking 15/49 (30.6%) 42/96 (43.8%) 0.126 
Smoking cessation rate among smokers 
at baseline 
2/17 (11.8%) 10/49 (20.4%) 0.714 
No. of drug-drug Interactions     
0 39 (78%) 88 (92.6%) 0.028 
1 10 (20%) 7 (7.4%)  
2 1 (2%) 0 (0%)  
Mean (SD) 0.24 (0.48) 0.07 (0.26) 0.0231 
0.4322 
Change from baseline3     
-2 1/17 (5.9%) 1/12 (8.3%) 0.931 
-1 5/17 (29.4%) 4/12 (33.3%)  
0 11/17 (64.7%) 7/12 (58.3%)  
Mean (SD) -0.35 (1.06) -0.42 (1.08) 0.875 
CD4 level ≥ 500 33 (66%) 58 (60.4%) 0.648 
Viral load level >500 copies/mL 6 (12%) 13 (13.5%) 0.793 
Cost estimates (USD)    
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1Independent t-test 
2General linear model was performed to adjust for covariate: baseline no. of drug-drug 
interactions (p<0.001) 
3Only for those who had drug-drug interactions at baseline 
Pharmacist Impact on HIV Co-Morbidities 
28 
 









Estimates of Costs 
Salaries† Ref. $55 --- $55/hour 
Total Costs Ref. $55   
Estimates of Benefits 
Systolic blood pressure57     
Change from baseline 








Diastolic blood pressure57     
Change from baseline 








LDL cholesterol58 (mg/dL)     
Change from baseline 





$35 per 1%  
LDL-C decrease  
(in 2006) 
$47 per 1%  
LDL-C 
decrease 
A1c59     
Change from baseline 





$1145 per 1% 
A1c lowering 
(in 2011) 
$1283 per 1% 
A1c lowering 
# Smoking cessation60  2/17 10/49   
Potential cost saving $365 $634 $3,105/quit  
(in 2015) 
--- 
# Drug-drug interactions61      
Change from baseline 





$910 (in 2013) 
 
$953 
Total potential cost savings $698 $4984   
Potential Benefit^ Ref. $4286   
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Sensitivity Analysisᵟ $1655 $4984   
Total Benefitᵟ ref $3329   
*Cost conversions are based on Consumer Price Index (Medical Care component), 
Bureau of Labor Statistics; †Assumed 20 min/visit and 3 visits/patient; ᵟ Negative 
outcomes ignored; ^ May be over-estimated 
 
 
 
 
 
 
